Pasar al contenido principal

LA CASCADA EPIGENETICA DE INFECCIONES VIRALES NEUROTROPICAS

PID2020-119710RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Sirtuin-2, NAD-Dependent Deacetylase, is a new potential therapeutic target for HIV-1 infection and HIV-Related Neurological Dysfunction

  • Duran-Castells, Clara
  • Kobayashi-Ishihara, Mie
  • Meyerhans, Andreas
  • Ruiz Riol, Marta
The implementation and access to combined antiretroviral treatment (cART) have dramatically improved the quality of life of people living with HIV (PLWH). However, some comorbidities, such as neurological disorders associated with HIV infection still represent a serious clinical challenge. Soluble factors in plasma that are associated with control of HIV replication and neurological dysfunction could serve as early biomarkers and as new therapeutic targets for this comorbidity. We used a customized antibody array for determination of blood plasma factors in 40 untreated PLWH with different levels of viremia and found sirtuin-2 (SIRT2), an NAD-dependent deacetylase, to be strongly associated with elevated viral loads and HIV provirus levels, as well as with markers of neurological damage (a-synuclein [SNCA], brain-derived neurotrophic factor [BDNF], microtubule-associated protein tau [MAPT], and neurofilament light protein [NFL]). Also, longitudinal analysis in HIV-infected individuals with immediate (n = 9) or delayed initiation (n = 10) of cART revealed that after 1 year on cART, SIRT2 plasma levels differed between both groups and correlated inversely with brain orbitofrontal cortex involution. Furthermore, targeting SIRT2 with specific small-molecule inhibitors in in vitro systems using J-LAT A2 and primary glial cells led to diminished HIV replication and virus reactivation from latency. Our data thus identify SIRT2 as a novel biomarker of uncontrolled HIV infection, with potential impact on neurological dysfunction and offers a new therapeutic target for HIV treatment and cure. IMPORTANCE Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. High plasma levels of sirtuin-2 (SIRT2), an NAD+ deacetylase, were detected in uncontrolled HIV infection and were strongly associated with plasma viral load and proviral levels. In parallel, SIRT2 levels in the peripheral blood and CNS were associated with markers of neurological damage and brain involution and were more pronounced in individuals who initiated cART later in infection. In vitro infection experiments using specific SIRT2 inhibitors suggest that specific targeting of SIRT2 could offer new therapeutic treatment options for HIV infections and their associated neurological dysfunction., This work was supported by grants from the Ministerio de Ciencia e Innovación (SAF2012-32078 and PID2020-119710RB-I00), the European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020, European Commission (EPIVINF-GA6932308), NIH grant P01-AI131568, JR13/00024, the Institució Catalana de Recerca i Estudis Avançats; ICREA, Swedish State Support for Clinical Research (ALFGBG-717531) and a research agreement with Aelix Therapeutics and Grifols.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola
  • Pedreño-Lopez, Núria
  • Bracke, Carmen
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pradenas, Edwards
  • Trinité, Benjamin
  • Marfil, Silvia
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana
  • Escribà, Tuixent
  • Jimenez-Moyano, Esther
  • Peña, Ruth
  • Cedeño, Samandhy
  • Prado, Julia G.
  • Mothe, Beatriz
  • Brander, Christian
  • Izquierdo-Useros, Nuria
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Massanella, Marta
  • Benitez, Rosa María
  • Romero, Alba
  • Molina-Morant, Daniel
  • Blanco, Julià
  • Clotet, Bonaventura
  • Mateu, Lourdes
  • Pedro-Botet, María Luisa
  • Carrillo, Jorge
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola
  • Pedreño-Lopez, Núria
  • Bracke, Carmen
  • Ávila-Nieto, Carlos
  • Rodríguez de la Concepción, María Luisa
  • Pradenas, Edwards
  • Trinité, Benjamin
  • Marfil, Silvia
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana
  • Escribà, Tuixent
  • Jimenez-Moyano, Esther
  • Peña, Ruth
  • Cedeño, Samandhy
  • Prado, Julia G.
  • Mothe, Beatriz
  • Brander, Christian
  • Izquierdo-Useros, Nuria
  • Serra Gironella, Joan
  • Segalés, Joaquim
  • Massanella, Marta
  • Benitez, Rosa María
  • Romero, Alba
  • Molina-Morant, Daniel
  • Blanco, Julià
  • Clotet, Bonaventura
  • Mateu, Lourdes
  • Pedro-Botet, María Luisa
  • Carrillo, Jorge
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n = 9), common variable immunodeficiency (CVID, n = 12), combined immunodeficiency (CID, n = 1), and thymoma with immunodeficiency (TID, n = 1). unPAD patients and healthy controls (HCs, n = 10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Of interest, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+T cells. CID and TID patients developed cellular but not humoral responses. Although the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Sirtuin-2, NAD-Dependent Deacetylase, is a new potential therapeutic target for HIV-1 infection and HIV-Related Neurological Dysfunction

  • Duran-Castells, Clara
  • Kobayashi-Ishihara, Mie
  • Meyerhans, Andreas
  • Ruiz Riol, Marta
The implementation and access to combined antiretroviral treatment (cART) have dramatically improved the quality of life of people living with HIV (PLWH). However, some comorbidities, such as neurological disorders associated with HIV infection still represent a serious clinical challenge. Soluble factors in plasma that are associated with control of HIV replication and neurological dysfunction could serve as early biomarkers and as new therapeutic targets for this comorbidity. We used a customized antibody array for determination of blood plasma factors in 40 untreated PLWH with different levels of viremia and found sirtuin-2 (SIRT2), an NAD-dependent deacetylase, to be strongly associated with elevated viral loads and HIV provirus levels, as well as with markers of neurological damage (a-synuclein [SNCA], brain-derived neurotrophic factor [BDNF], microtubule-associated protein tau [MAPT], and neurofilament light protein [NFL]). Also, longitudinal analysis in HIV-infected individuals with immediate (n = 9) or delayed initiation (n = 10) of cART revealed that after 1 year on cART, SIRT2 plasma levels differed between both groups and correlated inversely with brain orbitofrontal cortex involution. Furthermore, targeting SIRT2 with specific small-molecule inhibitors in in vitro systems using J-LAT A2 and primary glial cells led to diminished HIV replication and virus reactivation from latency. Our data thus identify SIRT2 as a novel biomarker of uncontrolled HIV infection, with potential impact on neurological dysfunction and offers a new therapeutic target for HIV treatment and cure. IMPORTANCE Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. High plasma levels of sirtuin-2 (SIRT2), an NAD+ deacetylase, were detected in uncontrolled HIV infection and were strongly associated with plasma viral load and proviral levels. In parallel, SIRT2 levels in the peripheral blood and CNS were associated with markers of neurological damage and brain involution and were more pronounced in individuals who initiated cART later in infection. In vitro infection experiments using specific SIRT2 inhibitors suggest that specific targeting of SIRT2 could offer new therapeutic treatment options for HIV infections and their associated neurological dysfunction., This work was supported by grants from the Ministerio de Ciencia e Innovación (SAF2012-32078 and PID2020-119710RB-I00), the European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020, European Commission (EPIVINF-GA6932308), NIH grant P01-AI131568, JR13/00024, the Institució Catalana de Recerca i Estudis Avançats; ICREA, Swedish State Support for Clinical Research (ALFGBG-717531) and a research agreement with Aelix Therapeutics and Grifols.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals

  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Bracke Manzanares, Carmen|||0000-0002-0306-8321
  • Avila-Nieto, Carlos
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Miranda, Cristina
  • González, Sandra
  • Toledo, Ruth
  • Font, Marta
  • Benet, Susana|||0000-0002-2219-8826
  • Escribà, Tuixent|||0000-0001-9467-7802
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Peña, Ruth
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Prado, Julia G.|||0000-0002-5439-4645
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Massanella, Marta|||0000-0002-3326-151X
  • Benítez Díaz, Rosa María|||0000-0001-6972-6094
  • Romero, Alba
  • Molina-Morant, Daniel|||0000-0002-4102-1065
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Pedro Botet, Maria Luisa|||0000-0001-7252-3191
  • Carrillo, Jorge|||0000-0003-0221-5948
Mass vaccination campaigns reduced COVID-19 incidence and severity. Here, we evaluated the immune responses developed in SARS-CoV-2-uninfected patients with predominantly antibody-deficiencies (PAD) after three mRNA-1273 vaccine doses. PAD patients were classified based on their immunodeficiency: unclassified primary antibody-deficiency (unPAD, n=9), common variable immunodeficiency (CVID, n=12), combined immunodeficiency (CID, n=1), and thymoma with immunodeficiency (TID, n=1). unPAD patients and healthy controls (HCs, n=10) developed similar vaccine-induced humoral responses after two doses. However, CVID patients showed reduced binding and neutralizing titers compared to HCs. Interestingly, these PAD groups showed lower levels of Spike-specific IFN-γ-producing cells. CVID individuals also presented diminished CD8+ T cells. CID and TID patients developed cellular but not humoral responses. While the third vaccine dose boosted humoral responses in most PAD patients, it had limited effect on expanding cellular immunity. Vaccine-induced immune responses in PAD individuals are heterogeneous, and should be immunomonitored to define a personalized therapeutic strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction

  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Kawana-Tachikawa, Ai|||0000-0002-3082-5324
  • Prats, Anna|||0000-0002-3586-4525
  • Martinez-Zalacain, Ignacio
  • Kobayashi-Ishihara, Mie|||0000-0001-6342-9451
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Peña, Ruth
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Silva-Arrieta, Sandra
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Ballana, Ester|||0000-0002-5215-7363
  • Prado, Julia G.|||0000-0002-5439-4645
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Sanchez, Jorge
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Hartigan-O'Connor, Dennis
  • Wyss-Coray, Tony
  • Meyerhans, Andreas|||0000-0003-0620-5317
  • Gisslén, Magnus
  • Price, Richard W.
  • Soriano-Mas, Carles|||0000-0003-4574-6597
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
The implementation and access to combined antiretroviral treatment (cART) have dramatically improved the quality of life of people living with HIV (PLWH). However, some comorbidities, such as neurological disorders associated with HIV infection still represent a serious clinical challenge. Soluble factors in plasma that are associated with control of HIV replication and neurological dysfunction could serve as early biomarkers and as new therapeutic targets for this comorbidity. We used a customized antibody array for determination of blood plasma factors in 40 untreated PLWH with different levels of viremia and found sirtuin-2 (SIRT2), an NAD-dependent deacetylase, to be strongly associated with elevated viral loads and HIV provirus levels, as well as with markers of neurological damage (a-synuclein [SNCA], brain-derived neurotrophic factor [BDNF], microtubule-associated protein tau [MAPT], and neurofilament light protein [NFL]). Also, longitudinal analysis in HIV-infected individuals with immediate (n = 9) or delayed initiation (n = 10) of cART revealed that after 1 year on cART, SIRT2 plasma levels differed between both groups and correlated inversely with brain orbitofrontal cortex involution. Furthermore, targeting SIRT2 with specific small-molecule inhibitors in in vitro systems using J-LAT A2 and primary glial cells led to diminished HIV replication and virus reactivation from latency. Our data thus identify SIRT2 as a novel biomarker of uncontrolled HIV infection, with potential impact on neurological dysfunction and offers a new therapeutic target for HIV treatment and cure. IMPORTANCE Neurocognitive disorders are frequently reported in people living with HIV (PLWH) even with the introduction of combined antiretroviral treatment (cART). To identify biomarkers and potential therapeutic tools to target HIV infection in peripheral blood and in the central nervous system (CNS), plasma proteomics were applied in untreated chronic HIV-infected individuals with different levels of virus control. High plasma levels of sirtuin-2 (SIRT2), an NAD + deacetylase, were detected in uncontrolled HIV infection and were strongly associated with plasma viral load and proviral levels. In parallel, SIRT2 levels in the peripheral blood and CNS were associated with markers of neurological damage and brain involution and were more pronounced in individuals who initiated cART later in infection. In vitro infection experiments using specific SIRT2 inhibitors suggest that specific targeting of SIRT2 could offer new therapeutic treatment options for HIV infections and their associated neurological dysfunction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination

  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Prats, Anna|||0000-0002-3586-4525
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Gálvez, Cristina|||0000-0002-2286-6193
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Ballana, Ester|||0000-0002-5215-7363
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Hanke, Thomas
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
  • Ruiz Riol, Marta|||0000-0003-1899-8879
Biomarkers predicting the outcome of HIV-1 virus control in natural infection and after therapeutic interventions in HIV-1 cure trials remain poorly defined. The BCN02 trial (NCT02616874), combined a T-cell vaccine with romidepsin (RMD), a cancer-drug that was used to promote HIV-1 latency reversal and which has also been shown to have beneficial effects on neurofunction. We conducted longitudinal plasma proteomics analyses in trial participants to define biomarkers associated with virus control during monitored antiretroviral pause (MAP) and to identify novel therapeutic targets that can improve future cure strategies. BCN02 was a phase I, open-label, single-arm clinical trial in early-treated, HIV infected individuals. Longitudinal plasma proteomes were analyzed in 11 BCN02 participants, including 8 participants that showed a rapid HIV-1 plasma rebound during a monitored antiretroviral pause (MAP-NC, 'non-controllers') and 3 that remained off ART with sustained plasma viremia <2000 copies/ml (MAP-C, 'controllers'). Inflammatory and neurological proteomes in plasma were evaluated and integration data analysis (viral and neurocognitive parameters) was performed. Validation studies were conducted in a cohort of untreated HIV-1+ individuals (n = 96) and in vitro viral replication assays using an anti-CD33 antibody were used for functional validation.